Back to Search
Start Over
Health-related quality of life in patients given ciltacabtagene autoleucel for relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b–2, open-label study
- Source :
- The Lancet Haematology; December 2022, Vol. 9 Issue: 12 pe897-e905, 9p
- Publication Year :
- 2022
-
Abstract
- CARTITUDE-1 is a phase 1b–2 study evaluating ciltacabtagene autoleucel (cilta-cel), a chimeric antigen receptor T cell therapy with two B-cell maturation antigen–targeting single-domain antibodies, in patients with relapsed or refractory multiple myeloma. Primary efficacy outcomes have previously been reported. Here, we report health-related quality of life (HRQOL) secondary outcomes evaluated using patient-reported outcomes.
Details
- Language :
- English
- ISSN :
- 23523026
- Volume :
- 9
- Issue :
- 12
- Database :
- Supplemental Index
- Journal :
- The Lancet Haematology
- Publication Type :
- Periodical
- Accession number :
- ejs61346250
- Full Text :
- https://doi.org/10.1016/S2352-3026(22)00284-8